Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biogen Idec Inc (BIIB) & TESARO Inc (TSRO): Top Biotech Stocks from Robyn Karnauskas Of Deutsche Bank

In the back drop of the biotech S&P ETF impacted by the S&P shedding market valuation by close to 7 % this week, Robyn Karnauskas who heads Deutsche Bank’s biotechnology vertical as its director spoke to CNBC and provided tips to investors on the likely biotech performers in the small cap and big cap categories in the immediate future.

Under the large cap category, Karnauskas mentioned the Cambridge headquartered Biogen Idec Inc (NASDAQ:BIIB) as a likely outperformer. She summarized that the impending launch of its much awaited haemophilia drug will drive up valuations in this drug maker’s stock. She went on to estimate that the price target on the stock of this $75 billion market capped firm would jump up in the $30 to $100 region per share, from its current valuations over the next two quarters, primarily driven by the underlying lower valuation of the stock.

Biogen Idec Inc (NASDAQ:BIIB)

Therefore, Karnauskas recommended the stock to investors by explaining that she foresaw “only upside on this stock.”  and no downside in the numbers. She further went on to underscore that the valuation jump “expectations are very low. Since the proof of concept for the biology here”

Under the small cap category, Karnauskas picked TESARO Inc (NASDAQ:TSRO), with a market cap of $1.14 billion. She listed out three key reasons as to why she thinks investors should buy into the stock at these levels.

The first point of attraction in the stock of TESARO Inc (NASDAQ:TSRO) for Karnauskas was the fact that the company is  expected to release a drug by the beginning of next year, on the back of strong clinical trial data.

The second point of import that Karnauskas pointed out was the fact that the company has a second drug candidate for ovarian cancer, which is also looking very promising and expects this to be launched next year.

She went on to predict that this drug has the potential to earn the company in the region of $200 million to $3 billion. She further highlighted the fact that TESARO Inc (NASDAQ:TSRO) has a exceptional management team, which has prior experience in growing drug firms and selling them at huge marked up pricing.  She also pointed that TESARO has a big chance to be a takeover target in the future.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!